首页 | 本学科首页   官方微博 | 高级检索  
     

胃肠间质瘤个体化治疗策略的探讨
引用本文:王健,沈朝勇,张波. 胃肠间质瘤个体化治疗策略的探讨[J]. 中华结直肠疾病电子杂志, 2019, 8(3): 217-220. DOI: 10.3877/cma.j.issn.2095-3224.2019.03.001
作者姓名:王健  沈朝勇  张波
作者单位:1. 610041 成都,四川大学华西医院胃肠外科
基金项目:国家自然科学基金面上项目(No.81572931)
摘    要:胃肠间质瘤(GIST)是最常见的胃肠道间叶源性肿瘤,多见于胃和小肠,GIST多具有恶性潜能,生物学行为可以从良性到高度恶性不等。GIST的预后与肿瘤的发病部位、瘤体大小、核分裂数以及肿瘤是否破裂密切相关,伊马替尼辅助治疗明显延长了GIST患者的生存时间。近年对于GIST患者实施个体化治疗的理念也得到了越来越多的重视,本文就GIST个体化治疗的策略研究进行阐述。

关 键 词:胃肠间质瘤  小肠  个体化治疗  伊马替尼  
收稿时间:2018-10-15

Individualized treatment strategy for gastrointestinal stromal tumor
Jian Wang,Chaoyong Shen,Bo Zhang. Individualized treatment strategy for gastrointestinal stromal tumor[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 8(3): 217-220. DOI: 10.3877/cma.j.issn.2095-3224.2019.03.001
Authors:Jian Wang  Chaoyong Shen  Bo Zhang
Affiliation:1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
Abstract:Gastrointestinal stromal tumor (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, and are commonly located in the stomach and small intestine. All GIST have malignant potential, ranging from small lesions with a benign behavior to highly malignant sarcomas. The prognosis of gastrointestinal stromal tumor is closely related to the tumor location、tumor size、mitotic count and rupture of the tumors. Adjuvant therapy with imatinib has significantly prolonged the survival time of GIST patients. Recently, more and more attention has been paid to the concept of individualized treatment for gastrointestinal stromal tumor. And this article reviews the strategy of individualized treatment for gastrointestinal stromal tumor.
Keywords:Gastrointestinal stromal tumor  Small intestine  Individualized treatment  Imatinib  
点击此处可从《中华结直肠疾病电子杂志》浏览原始摘要信息
点击此处可从《中华结直肠疾病电子杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号